Veterinary anaesthesia and analgesia · 2024
Influence of acepromazine on the cardiovascular effects of dobutamine in isoflurane-anaesthetised horses premedicated with romifidine.
СтатьяRandomized Controlled Trial, VeterinaryНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Wong Adrian M, Schier Mara F, Hosgood Giselle, Drynan Eleanor, Raisis Anthea L
Аннотация
OBJECTIVE: To explore the influence of acepromazine on the cardiovascular effects of dobutamine in isoflurane-anaesthetised horses premedicated with romifidine.
STUDY DESIGN: Prospective randomised clinical trial.
ANIMALS: A total of 18 horses undergoing elective arthroscopy were enrolled, of which 12 horses requiring dobutamine were included.
METHODS: Horses were randomised to receive acepromazine 0.02 mg kg-1 (Group A+) intravenously (IV) or none (Group A-), 35 minutes before anaesthesia. Horses received xylazine 0.2 mg kg-1 concurrently to facilitate IV access. Horses were premedicated with romifidine 0.08 mg kg-1, induced with ketamine 2.2 mg kg-1 and diazepam 0.08 mg kg-1 IV, and maintained with isoflurane in oxygen. Dobutamine infusion was commenced when mean arterial pressure (MAP) was < 60 mmHg. Cardiovascular data were collected prior to dobutamine, and at a target MAP of ≥ 70 mmHg. Dobutamine start time from induction, duration and dose to reach target MAP were compared using Mann-Whitney U test. Cardiovascular variables were compared using repeated measures ANOVA and post-hoc Fisher's least significant difference test.
RESULTS: Cardiac index (CI) and its percentage change from baseline were significantly higher at target MAP in group A+ [62.0 (49.9-74.2) mL minute-1 kg-1; 42.8 (17.0-68.7) %] than in A- [49.5 (39.6-59.5) mL minute-1 kg-1; -4.05 (-21.2-13.0) %] (p = 0.049; p = 0.003). Group A+ required significantly earlier dobutamine [20 (18-25) minutes] than group A- [36 (27-60) minutes] (p = 0.02). Group A+ required significantly higher dobutamine dose [1.5 (1-2.5) μg kg-1 minute-1] to reach target MAP than group A- [0.5 (0.5-1) μg kg-1 minute-1] (p = 0.009).
CONCLUSION AND CLINICAL RELEVANCE: Dobutamine significantly increased MAP and CI following pre-anaesthetic acepromazine sedation, in isoflurane-anaesthetised horses premedicated with romifidine. Without acepromazine, dobutamine increased MAP but not CI. Interactions between acepromazine, romifidine and dobutamine on the cardiovascular system should be considered.
STUDY DESIGN: Prospective randomised clinical trial.
ANIMALS: A total of 18 horses undergoing elective arthroscopy were enrolled, of which 12 horses requiring dobutamine were included.
METHODS: Horses were randomised to receive acepromazine 0.02 mg kg-1 (Group A+) intravenously (IV) or none (Group A-), 35 minutes before anaesthesia. Horses received xylazine 0.2 mg kg-1 concurrently to facilitate IV access. Horses were premedicated with romifidine 0.08 mg kg-1, induced with ketamine 2.2 mg kg-1 and diazepam 0.08 mg kg-1 IV, and maintained with isoflurane in oxygen. Dobutamine infusion was commenced when mean arterial pressure (MAP) was < 60 mmHg. Cardiovascular data were collected prior to dobutamine, and at a target MAP of ≥ 70 mmHg. Dobutamine start time from induction, duration and dose to reach target MAP were compared using Mann-Whitney U test. Cardiovascular variables were compared using repeated measures ANOVA and post-hoc Fisher's least significant difference test.
RESULTS: Cardiac index (CI) and its percentage change from baseline were significantly higher at target MAP in group A+ [62.0 (49.9-74.2) mL minute-1 kg-1; 42.8 (17.0-68.7) %] than in A- [49.5 (39.6-59.5) mL minute-1 kg-1; -4.05 (-21.2-13.0) %] (p = 0.049; p = 0.003). Group A+ required significantly earlier dobutamine [20 (18-25) minutes] than group A- [36 (27-60) minutes] (p = 0.02). Group A+ required significantly higher dobutamine dose [1.5 (1-2.5) μg kg-1 minute-1] to reach target MAP than group A- [0.5 (0.5-1) μg kg-1 minute-1] (p = 0.009).
CONCLUSION AND CLINICAL RELEVANCE: Dobutamine significantly increased MAP and CI following pre-anaesthetic acepromazine sedation, in isoflurane-anaesthetised horses premedicated with romifidine. Without acepromazine, dobutamine increased MAP but not CI. Interactions between acepromazine, romifidine and dobutamine on the cardiovascular system should be considered.